CN104107280A - Pharmaceutical composition for treating chronic pelvic inflammation, and preparation method and application thereof - Google Patents
Pharmaceutical composition for treating chronic pelvic inflammation, and preparation method and application thereof Download PDFInfo
- Publication number
- CN104107280A CN104107280A CN201410314964.3A CN201410314964A CN104107280A CN 104107280 A CN104107280 A CN 104107280A CN 201410314964 A CN201410314964 A CN 201410314964A CN 104107280 A CN104107280 A CN 104107280A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- chronic pelvic
- treatment
- inflammatory disease
- pelvic inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a pharmaceutical composition for treating chronic pelvic inflammation, and a preparation method and application thereof. Each dose of the pharmaceutical composition comprises the following components by mass: 15 to 20 g of honeysuckle flower, 15 to 20 g of fructus forsythiae, 15 to 20 g of patrinia herb, 20 to 25 g of rhizoma corydalis, 15 to 20 g of Sichuan chinaberry fruit, 10 to 15 g of folium isatidis, 5 to 10 g of Tokyo violet herb, 10 to 15 g of Chinese angelica, 15 to 20 g of motherwort and 10 to 15 g of red peony root. The components of the pharmaceutical composition are mutually compatible, perform respective efficacy and can form effective combination for deep treatment of chronic pelvic inflammation, exerting menstruation-regulating, qi-rectifying, blood stasis-dispersing, pain-relieving, heat-clearing and dampness-draining effects and the like. The pharmaceutical composition has the advantages of simple composition, easy administration, low cost, fast action in treatment of chronic pelvic inflammation and a high cure rate of chronic pelvic inflammation.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition and its preparation method and application, especially relate to a kind of pharmaceutical composition that is used for the treatment of chronic pelvic inflammatory disease and its preparation method and application, belong to Chinese medicine formula technical field.
Background technology
Pelvic inflammatory disease is woman common disease, i.e. the general name of female internal genital organs and connective tissue around thereof, pelvic peritoneum inflammation.Take clinically prolonged and repeated outbreak lower abdomen and flank pain tenesmus, leucorrhoea grow in quantity, have abnormal flavour, menoxenia, dysmenorrhea as main, and with General Symptomies such as fatigue and weakness, low grade fever or aversion to cold in various degree.Primary disease fecund is born in puerperal, post-abortion, cut open palace puerperal and gynecologic surgery antibacterial enters traumatic infection and falls ill.Pelvic inflammatory disease has acute and chronic dividing, and micro-anxious, the serious symptom of acute onset, as treatment not in time, can cause diffuse peritonitis, septicemia etc., and severe patient can threat to life.And if in acute stage, cured thoroughly, develop into chronic pelvic inflammatory disease.At present, a lot of women are standing the torment of chronic pelvic inflammatory disease, because it shows effect repeatedly, and prolongedly more to patient, have not brought very large puzzlement and misery.
Summary of the invention
For solving the deficiencies in the prior art, the object of the present invention is to provide a kind of can effectively treat chronic pelvic inflammatory disease and toxic and side effects little be used for the treatment of pharmaceutical composition of chronic pelvic inflammatory disease and its preparation method and application.
For achieving the above object, the present invention is achieved by the following technical solutions:
A pharmaceutical composition that is used for the treatment of chronic pelvic inflammatory disease, is characterized in that, every dose of Chinese medicine preparation comprises that the quality of following component and each component is respectively:
Flos Lonicerae: 15-20g;
Fructus Forsythiae: 15-20g;
Herba Patriniae: 15-20g;
Rhizoma Corydalis: 20-25g;
Fructus Toosendan: 15-20g;
Folium Isatidis: 10-15g;
Herba Violae: 5-10g;
Radix Angelicae Sinensis: 10-15g;
Herba Leonuri: 15-20g;
Radix Paeoniae Rubra: 10-15g.
Above-mentioned a kind of pharmaceutical composition that is used for the treatment of chronic pelvic inflammatory disease, is characterized in that, comprises that the quality of each component in following component and every dose of Chinese medicine formula is respectively:
Flos Lonicerae: 18g;
Fructus Forsythiae: 18g;
Herba Patriniae: 18g;
Rhizoma Corydalis: 22g;
Fructus Toosendan: 15g;
Folium Isatidis: 15g;
Herba Violae: 8g;
Radix Angelicae Sinensis: 12g;
Herba Leonuri: 20g;
Radix Paeoniae Rubra: 10g.
Further, the preparation method of the above-mentioned pharmaceutical composition that is used for the treatment of chronic pelvic inflammatory disease, is characterized in that: by each component in Chinese medicine preparation according to above-mentioned mass mixing after, add being decocted in water for oral dose of 3 times of Chinese medicine preparation gross weights, then filter and obtain medicinal liquid.
In addition the application of the pharmaceutical composition that, above-mentioned manufacture method prepares in treatment chronic pelvic inflammatory disease.
The invention has the beneficial effects as follows: the mutual compatibility of each component during Chinese medicine formula of the present invention forms, in himself effect of performance, effectively combination is deeply treated chronic pelvic inflammatory disease, has that regulating menstruation is regulated the flow of vital energy, an effect of blood-activating analgetic, clearing away heat-damp and promoting diuresis.And prescription of the present invention is easy, be easy to take, cost is low, make that responding well to treatment of chronic pelvic inflammatory disease is fast, cure rate is high.
The specific embodiment
Below in conjunction with specific embodiment, the present invention is done to concrete introduction.
Prescription analysis:
In Chinese medicine preparation prescription of the present invention: described Flos Lonicerae, Fructus Forsythiae, Herba Patriniae have the effect of heat-clearing and toxic substances removing, blood stasis dispelling regulating menstruation, eliminating dampness by diuresis leukorrhagia stopping, and the effective alleviating pain of Rhizoma Corydalis, Fructus Toosendan, Folium Isatidis and Herba Violae have the effect of removing heat from blood, in addition, described Radix Angelicae Sinensis, Herba Leonuri and Radix Paeoniae Rubra have clearing away heat-damp and promoting diuresis, antalgic, promote that blood is unobstructed, be particularly advantageous in elimination lump.Above after the mutual compatibility of each component, have that regulating menstruation is regulated the flow of vital energy, the remarkable efficacy of blood-activating analgetic, clearing away heat-damp and promoting diuresis.
Embodiment 1:
By every dose of pharmaceutical composition that is used for the treatment of chronic pelvic inflammatory disease, according to Flos Lonicerae: 15g; Fructus Forsythiae: 15g; Herba Patriniae: 20g; Rhizoma Corydalis: 20g; Fructus Toosendan: 15g; Folium Isatidis: 10g; Herba Violae: 10g; Radix Angelicae Sinensis: 10g; Herba Leonuri: 20g; Radix Paeoniae Rubra: 10g adds being decocted in water for oral dose of 3 times of Chinese medicine preparation gross weights after mixing, and then filters and obtains medicinal liquid.
Embodiment 2:
By every dose of pharmaceutical composition that is used for the treatment of chronic pelvic inflammatory disease, according to Flos Lonicerae: 20g; Fructus Forsythiae: 0g; Herba Patriniae: 15g; Rhizoma Corydalis: 25g; Fructus Toosendan: 20g; Folium Isatidis: 10g; Herba Violae: 5g; Radix Angelicae Sinensis: 15g; Herba Leonuri: 15g; Radix Paeoniae Rubra: 15g adds being decocted in water for oral dose of 3 times of Chinese medicine preparation gross weights after mixing, and then filters and obtains medicinal liquid.
Embodiment 3:
By every dose of pharmaceutical composition that is used for the treatment of chronic pelvic inflammatory disease, according to Flos Lonicerae: 18g; Fructus Forsythiae: 18g; Herba Patriniae: 18g; Rhizoma Corydalis: 22g; Fructus Toosendan: 18g; Folium Isatidis: 12g; Herba Violae: 8g; Radix Angelicae Sinensis: 12g; Herba Leonuri: 18g; Radix Paeoniae Rubra: 12g adds being decocted in water for oral dose of 3 times of Chinese medicine preparation gross weights after mixing, and then filters and obtains medicinal liquid.
Embodiment 4:
By every dose of pharmaceutical composition that is used for the treatment of chronic pelvic inflammatory disease, according to Flos Lonicerae: 18g; Fructus Forsythiae: 18g; Herba Patriniae: 18g; Rhizoma Corydalis: 22g; Fructus Toosendan: 15g; Folium Isatidis: 15g; Herba Violae: 8g; Radix Angelicae Sinensis: 12g; Herba Leonuri: 20g; Radix Paeoniae Rubra: 10g adds being decocted in water for oral dose of 3 times of Chinese medicine preparation gross weights after mixing, and then filters and obtains medicinal liquid.
Clinical effectiveness for checking preparation of the present invention, has carried out clinical experiment.
1, diagnosis:
Lower abdomen paroxysmal pain shows effect, accompanies that waist cold type of pain, leucorrhea are many repeatedly, yellow skin, stench taste.Gynecologial examination: vaginal wall is congested, and yellow secretions is more, cervix uteri is smooth, palace body anteposition, often large, movable not good enough, light tenderness; Bilateral adnexa slightly thickens, tenderness, and Western medicine diagnose is chronic pelvic inflammatory disease; Tcm symptom is: tongue dimness, yellow and greasy fur, deep-thready pulse.
2, clinical data:
Case: 52 examples, age 28-45 year, not etc. 32 years old mean age, chronic pelvic inflammatory disease medical history 2-6 was not etc.Above-mentioned patient is divided into four treatment groups.Every group is respectively 13 people.
3, efficacy assessment standard:
Cure: chronic pelvic inflammatory disease symptom disappears, drug withdrawal is not recurrence after 2 years;
Effective: chronic pelvic inflammatory disease symptom disappears, drug withdrawal is not recurrence after 1 year;
Effective: chronic pelvic inflammatory disease symptom disappears, drug withdrawal is not recurred after half a year;
Invalid: unchanged.
4, Therapeutic Method:
Wherein take the pharmaceutical composition that the embodiment of the present invention 1 prepares for first group, take the pharmaceutical composition that embodiment 2 prepares for second group, take the pharmaceutical composition that embodiment 3 prepares for the 3rd group, take the pharmaceutical composition that embodiment 4 prepares for the 4th group, instructions of taking is: every day potion, sooner or later take at twice, take continuously 15 doses.
5, result:
Table 1 is the contrast table of four groups of therapeutic effect:
| Group | Number of cases | Cure | Effective | Effectively | Invalid | Total effective rate (%) |
| First group | 13 | 8 | 3 | 2 | 0 | 100 |
| Second group | 13 | 7 | 5 | 1 | 0 | 100 |
| The 3rd group | 13 | 9 | 3 | 1 | 0 | 100 |
| The 4th group | 13 | 9 | 4 | 0 | 0 | 100 |
As shown in table 1: the effective percentage of pharmaceutical composition of the present invention is very high, all reached 100%, curative effect is very good.
Above-described embodiment does not limit the present invention in any form, and all employings are equal to replaces or technical scheme that the mode of equivalent transformation obtains, all drops in protection scope of the present invention.
Claims (4)
1. a pharmaceutical composition that is used for the treatment of chronic pelvic inflammatory disease, is characterized in that, every dose of Chinese medicine preparation comprises that the quality of following component and each component is respectively:
Flos Lonicerae: 15-20g;
Fructus Forsythiae: 15-20g;
Herba Patriniae: 15-20 g;
Rhizoma Corydalis: 20-25g;
Fructus Toosendan: 15-20g;
Folium Isatidis: 10-15g;
Herba Violae: 5-10g;
Radix Angelicae Sinensis: 10-15g;
Herba Leonuri: 15-20g;
Radix Paeoniae Rubra: 10-15g.
2. a kind of pharmaceutical composition that is used for the treatment of chronic pelvic inflammatory disease according to claim 1, is characterized in that, comprises that the quality of each component in following component and every dose of Chinese medicine formula is respectively:
Flos Lonicerae: 18g;
Fructus Forsythiae: 18g;
Herba Patriniae: 18 g;
Rhizoma Corydalis: 22g;
Fructus Toosendan: 15 g;
Folium Isatidis: 15g;
Herba Violae: 8g;
Radix Angelicae Sinensis: 12g;
Herba Leonuri: 20g;
Radix Paeoniae Rubra: 10g.
3. the preparation method of the pharmaceutical composition that is used for the treatment of chronic pelvic inflammatory disease described in a claim 1 or 2, it is characterized in that: by each component in Chinese medicine preparation according to above-mentioned mass mixing after, add being decocted in water for oral dose of 3 times of Chinese medicine preparation gross weights, then filter and obtain medicinal liquid.
4. the application of the pharmaceutical composition that manufacture method according to claim 3 prepares in treatment chronic pelvic inflammatory disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410314964.3A CN104107280A (en) | 2014-07-03 | 2014-07-03 | Pharmaceutical composition for treating chronic pelvic inflammation, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410314964.3A CN104107280A (en) | 2014-07-03 | 2014-07-03 | Pharmaceutical composition for treating chronic pelvic inflammation, and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104107280A true CN104107280A (en) | 2014-10-22 |
Family
ID=51704399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410314964.3A Pending CN104107280A (en) | 2014-07-03 | 2014-07-03 | Pharmaceutical composition for treating chronic pelvic inflammation, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104107280A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105288029A (en) * | 2015-12-10 | 2016-02-03 | 赵爱良 | Medicine for treating pelvic inflammation |
| CN105362577A (en) * | 2015-12-09 | 2016-03-02 | 赵爱良 | Navel patch for treating pelvic inflammation and preparation method thereof |
| CN107854572A (en) * | 2017-11-03 | 2018-03-30 | 河南省中医院（河南中医药大学第二附属医院） | External traditional Chinese medicine for treating damp-heat stasis type chronic pelvic inflammatory disease pain and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004002503A1 (en) * | 2002-06-27 | 2004-01-08 | Chinese Medicines Scientific Consultants Pty Ltd | Compositions and methods for treating gynaecological disorders |
| CN1634364A (en) * | 2004-11-22 | 2005-07-06 | 苟文丽 | Enema for treating pelvic inflammation and other disease |
| CN1709359A (en) * | 2005-06-24 | 2005-12-21 | 黄开启 | Tablet for treating women's pelvic inflammation and its preparing method |
-
2014
- 2014-07-03 CN CN201410314964.3A patent/CN104107280A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004002503A1 (en) * | 2002-06-27 | 2004-01-08 | Chinese Medicines Scientific Consultants Pty Ltd | Compositions and methods for treating gynaecological disorders |
| CN1634364A (en) * | 2004-11-22 | 2005-07-06 | 苟文丽 | Enema for treating pelvic inflammation and other disease |
| CN1709359A (en) * | 2005-06-24 | 2005-12-21 | 黄开启 | Tablet for treating women's pelvic inflammation and its preparing method |
Non-Patent Citations (4)
| Title |
|---|
| 成都市金牛区永丰卫生所: "《中草药单验方选编》", 30 September 1970, 成都市卫生局革命委员会 * |
| 李富生等: "《常见病中医临床治疗进展》", 31 December 1991, 中国中医药出版社 * |
| 马馨: "《百医百顺（奇方宝典B）》", 31 July 2006, 黑龙江人民出版社 * |
| 黄晓桃: "《常见妇科病中西医诊治案例精选》", 31 January 2014, 华中科技大学出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105362577A (en) * | 2015-12-09 | 2016-03-02 | 赵爱良 | Navel patch for treating pelvic inflammation and preparation method thereof |
| CN105288029A (en) * | 2015-12-10 | 2016-02-03 | 赵爱良 | Medicine for treating pelvic inflammation |
| CN107854572A (en) * | 2017-11-03 | 2018-03-30 | 河南省中医院（河南中医药大学第二附属医院） | External traditional Chinese medicine for treating damp-heat stasis type chronic pelvic inflammatory disease pain and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102872418B (en) | Medicine for treating pelvic inflammation | |
| CN102940721B (en) | Medicine for treating chronic pelvic inflammation | |
| CN104096163A (en) | External drug for maintenance and sanitation of ovary, inner labia and vulva of women | |
| CN103142879B (en) | Traditional Chinese medicine for treating rubella | |
| CN104107280A (en) | Pharmaceutical composition for treating chronic pelvic inflammation, and preparation method and application thereof | |
| CN104043022A (en) | Traditional Chinese medicine composition for treating gynecologic inflammation | |
| CN103800843A (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammation | |
| CN101804189B (en) | Drug for treating primary dysmenorrhea | |
| CN102205096B (en) | Medicament for treating adnexitis and pelvic inflammation | |
| CN102247567B (en) | Traditional Chinese medicine preparation for effectively treating urethritis | |
| CN104606592A (en) | Pharmaceutical preparation treating pelvic inflammation by using rhizoma smilacis glabrae and dandelions as main raw materials | |
| CN105456909A (en) | Traditional Chinese medicine composition for treating qi-stagnation and blood stasis adenomyosis | |
| CN104873866B (en) | A kind of Pu Ling basins inflammation health pharmaceutical preparation and its detection method for pelvic infecton | |
| CN108926672B (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus | |
| CN104435362A (en) | Traditional Chinese medicine compound for treating chronic pelvic inflammation | |
| CN104013876A (en) | Traditional Chinese medicine composition for treating pelvic inflammatory disease | |
| CN104606593A (en) | Preparation process of dandelion-rhizoma smilacis glabrae pelvic inflammation-curing capsule preparation | |
| CN112245528A (en) | Traditional Chinese medicine wound healing agent and preparation method thereof | |
| CN104257992A (en) | Traditional Chinese medicine composition for treating dysmenorrhea of women | |
| CN104258233A (en) | Traditional Chinese medicine for treating impetigo | |
| CN104324159A (en) | Traditional Chinese medicine agent for treating toxic-heat type acute lymphangitis | |
| CN103550592A (en) | Traditional Chinese medicinal effective part composition for treating priapism | |
| CN104107294A (en) | Traditional Chinese medicine preparation used for treating chronic bronchitis, and preparation method and application thereof | |
| CN115887540A (en) | Traditional Chinese medicine for treating sequelae of damp-heat stasis type pelvic inflammatory disease | |
| CN107715069A (en) | A kind of Chinese medicine composition for treating ectopic pregnancy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141022 |
|
| RJ01 | Rejection of invention patent application after publication |